Triggers and mechanisms of skeletal muscle wasting in chronic obstructive pulmonary disease.

Citation for published version (APA):

Document status and date:
Published: 01/01/2013

DOI:
10.1016/j.biocel.2013.06.015

Document Version:
Publisher's PDF, also known as Version of record

Document license:
Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:
www.umlib.nl/taverne-license

Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.

Download date: 21 Jun. 2022
Review

Triggers and mechanisms of skeletal muscle wasting in chronic obstructive pulmonary disease


NUTRIM School for Nutrition, Toxicology & Metabolism, Department of Respiratory Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands

A R T I C L E   I N F O

Article history:
Available online 1 July 2013

Keywords:
Muscle atrophy
Protein synthesis
Proteolysis
Myogenesis

A B S T R A C T

Skeletal muscle wasting contributes to impaired exercise capacity, reduced health-related quality of life and is an independent determinant of mortality in chronic obstructive pulmonary disease. An imbalance between protein synthesis and myogenesis on one hand, and muscle proteolysis and apoptosis on the other hand, has been proposed to underlie muscle wasting in this disease. In this review, the current understanding of the state and regulation of these processes governing muscle mass in this condition is presented. In addition, a conceptual mode of action of disease-related determinants of muscle wasting including disuse, hypoxia, malnutrition, inflammation and glucocorticoids is provided by overlaying the available associative clinical data with causal evidence, mostly derived from experimental models. Significant progress has been made in understanding and managing muscle wasting in chronic obstructive pulmonary disease. Further examination of the time course of muscle wasting and specific disease phenotypes, as well as the application of systems biology and omics approaches in future research will allow the development of tailored strategies to prevent or reverse muscle wasting in chronic obstructive pulmonary disease.

This article is part of a Directed Issue entitled: Molecular basis of muscle wasting.

© 2013 Elsevier Ltd. All rights reserved.

Contents

1. Introduction ............................................................................................................. 2246
2. Regulation of muscle mass maintenance in COPD: a matter of balance .......................................................... 2246
   2.1. Muscle protein turnover in COPD ...................................................................... 2246
      2.1.1. Muscle proteolysis regulation in COPD ..................................................... 2246
      2.1.2. Muscle protein synthesis regulation in COPD ......................................... 2247
   2.2. Myonuclear turnover in COPD ......................................................................... 2247
      2.2.1. Muscle cell apoptosis in COPD ................................................................. 2247
      2.2.2. Myonuclear accretion and muscle regeneration in COPD ......................... 2247

Abbreviations: 4E-BP1, 4E-binding protein-1; AA, amino acid; ALS, autophagy-lysosomal system; AMPK, adenosine monophosphate-activated protein kinase; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; ERK, extracellular signal regulated kinase; FFM, fat-free mass; FOXO, forkhead box O; GC, glucocorticoid; GR, glucocorticoid receptor; GSK3β, glycogen synthase kinase 3β; HIF-1α, hypoxia inducible factor 1α; HPA, hypothalamus-pituitary-adrenal axis; IGF-1, insulin-like growth factor-1; IL, interleukin; IRS-1, insulin receptor substrate-1; JNK, c-Jun N-terminal kinase; MAFA, muscle atrophy F-box; MAPK, mitogen activated protein kinase; mTOR, mammalian target of rapamycin; MuRF1, muscle RING finger protein; Nedd4, neural precursor cell expressed developmentally down-regulated protein 4; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells; P70S6K, p70S6 kinase; PARP, poly ADP ribose polymerase; PI-3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; REDD1, regulated in development and DNA damage responses-1; REE, resting energy expenditure; STAT, signal transducer and activator of transcription; TGF, transforming growth factor; TLR, Toll-like receptor; TNF-α, tumor necrosis factor-alpha; TSC2, tuberous suppressor complex 2; TWEAK, tumor necrosis factor-like weak inducer of apoptosis; Ub, ubiquitin; UPS, ubiquitin 26S-proteasome system.

* This article is part of a Directed Issue entitled: Molecular basis of muscle wasting.

† Corresponding author at: NUTRIM School for Nutrition, Toxicology & Metabolism, Department of Respiratory Medicine, Maastricht University Medical Center+, P.O. Box 5800, NL-6202 AZ Maastricht, The Netherlands. Tel.: +31 43 3884247; fax: +31 43 3875051.

E-mail addresses: r.langen@maastrichtuniversity.nl, a.schols@maastrichtuniversity.nl (R.C.J. Langen).

1357-2725/5 – see front matter © 2013 Elsevier Ltd. All rights reserved.

http://dx.doi.org/10.1016/j.biocel.2013.06.015
1. Introduction

Chronic obstructive pulmonary disease (COPD) is a lung disorder with progressive airflow obstruction resulting from inflammation and remodeling of the airways which often includes development of emphysema. Dominant symptoms are dyspnea and impaired exercise capacity adversely affecting health-related quality of life. COPD is characterized by episodes of acute worsening of symptoms referred to as exacerbations, which negatively affect disease progression (Tanabe et al., 2011) and survival (Soler-Cataluna et al., 2005). Although the lung is the primary diseased organ, COPD is increasingly acknowledged as a systemic disease due to its clinically significant extra-pulmonary consequences (Barnes and Celli, 2009). Systemic degenerative manifestations in COPD include osteoporosis (Romme et al., 2012) and muscle wasting. The prevalence of muscle atrophy is relatively high in COPD: 20–40% depending on definition and disease stage (Engelen et al., 1994; Schols et al., 1993). Moreover, as body composition is not routinely assessed, the prevalence of muscle atrophy most likely is underestimated as selective depletion of fat-free mass (FFM) despite relative preservation of fat mass is seen in a substantial proportion of patients with normal body weight (Engelen et al., 1999). Importantly, muscle wasting not only contributes to diminished muscle function, reduced exercise capacity and decreased health status (Baarends et al., 1997a; Mostert et al., 2000), but is also a determinant of mortality in COPD independent of airflow obstruction (Schols et al., 2005; Vestbo et al., 2006). In addition to muscle mass depletion, a shift in muscle fiber composition from type I to type II, accompanied by a decrease in oxidative capacity culminates in reduced muscle endurance. This not only contributes to reduced exercise capacity (Gosker et al., 2002; Maltais et al., 2000), but may also accelerate muscle wasting in COPD (Remels et al., 2012) since type II fibers are generally more susceptible to atrophy stimuli (as reviewed elsewhere in this issue). Muscle atrophy in COPD has been demonstrated by decreases in FFM at whole body level, but also specifically at the level of the extremities (Bernard et al., 1998). In addition, muscle atrophy is apparent as a decrease in the size of individual muscle fibers, and this muscle fiber atrophy in COPD seems selective for type II fibers in peripheral muscle (Caron et al., 2009; Gosker et al., 2002).

The last two decades have yielded some insight in the impairments of the processes governing muscle mass, i.e. protein- and myonuclear turnover, and identified putative triggers of muscle wasting in COPD. The current knowledge on the processes that govern muscle mass in relation to muscle wasting in COPD is mostly derived from (immuno)histochemical and biochemical analyses of patient muscle biopsies, and described in the first part of this review. A number of factors that may result in muscle atrophy have been implicated as potential triggers of muscle wasting in COPD. These include disuse, hypoxemia, malnutrition, inflammation, and glucocorticoids. In the second part of this review, the associative evidence between these putative triggers and muscle wasting in COPD, as well as the data derived from experimental models supporting a causal contribution of these factors to muscle wasting will be presented.

2. Regulation of muscle mass maintenance in COPD: a matter of balance

Muscle mass is determined by the net balance of muscle protein synthesis and protein breakdown with at least a supportive role of the balance between myonuclear loss and accretion determined by apoptosis of myonuclear nuclei and recruitment of myonuclei from muscle progenitor cells including satellite cells.

2.1. Muscle protein turnover in COPD

It is currently unclear whether reduced muscle protein synthesis, increased proteolysis or both are responsible for muscle atrophy in COPD. Increased protein turnover on the whole body level has been reported in COPD (Engelen et al., 2000a; Kao et al., 2011). This could reflect activation of muscle protein synthesis as a compensatory adaptation to increased muscle proteolysis in an attempt to maintain muscle mass. However, when assessing whole body protein turnover, the contribution of different compartments has to be considered. For instance, pulmonary remodeling, myelopoesis, and hepatic production of acute phase response proteins, are all energy-demanding processes involving increased protein synthesis, which may rely on amino acids (AA) provided by increased muscle proteolysis (Pereira et al., 2005). To illustrate this, when stratified for the presence of emphysema, which is characterized by active pulmonary remodeling, muscle leucine concentrations were decreased in emphysematous compared to non-emphysematous COPD patients (Engelen et al., 2000b).

2.1.1. Muscle proteolysis regulation in COPD

Whereas the studies in which muscle protein synthesis was measured are limited in COPD (Morrison et al., 1988), none exist on direct detection of muscle protein degradation rates. This is likely the consequence of technical challenges imposed by measuring muscle proteolysis; surrogate indices however have been reported in COPD. Whole body myofibrillar protein degradation was found to be increased in underweight patients compared to controls and normal-weight patients (Rutten et al., 2006). Additional indirect evidence for increased muscle proteolysis rate was shown in emphysematous and underweight COPD patients based on increased circulatory levels of 3-methylhistidine, which is a product of myofibrillar protein breakdown (Ubhi et al., 2011). Although our knowledge of muscle protein degradation and synthesis derived from direct muscle protein turnover measurements are limited in COPD, some insights can be distilled from studies in which the regulatory cues and pathways of these processes were investigated in muscle biopsies.

Several proteolytic systems in skeletal muscle appear to be involved in the degradation of myofibrillar proteins. The ubiquitin (Ub) 26S-proteasome system (UPS) is considered a rate-limiting proteolytic system involved in muscle atrophy. Protein degradation by the UPS relies on selective conjugation of Ub molecules to substrate protein by E3 Ub-ligases. These poly-Ub chains are subsequently recognized and degraded by the 26S-proteasome. Increased levels of Ub conjugation have been demonstrated in
biopsy homogenates of COPD patients with muscle atrophy compared to controls (Fermoselle et al., 2012; Lemire et al., 2012). In particular, muscle-specific E3 Ub-ligases atrogin-1 (or MAFbx) and muscle-specific RING finger protein 1 (MuRF1) are essential for muscle atrophy under various conditions (Glass, 2005). In COPD, atrogin-1 mRNA and protein levels, not MuRF1, were found increased in peripheral muscle of muscle-atrophied COPD patients compared to controls (Lemire et al., 2012; Plant et al., 2010) while atrogin-1 mRNA and protein as well as MuRF1 mRNA and total protein ubiquitination were increased in cachetic (i.e. muscle atrophied and underweight) patients compared to controls (Doucet et al., 2007; Fermoselle et al., 2012). Moreover, muscle atrogin-1 protein content was specifically increased in cachetic COPD patients compared to non-cachetic patients (Vogiatzis et al.). An additional E3 Ub-ligase, neural precursor cell expression developmentally down-regulated protein 4 (Nedd4), also displayed increased expression in muscle-atrophied patients with severe COPD compared to controls (Plant et al., 2010).

Atrogin-1 and MuRF1 are regulated by forkhead transcription factors FOXO-1 and -3 (Glass, 2005). Both FOXO-1 and FOXO-3 mRNA levels, as well as FOXO-1 nuclear content, were shown to be increased in peripheral muscle of cachetic and muscle-atrophied COPD patients compared to controls (Debigare et al., 2010; Doucet et al., 2007). In addition, regulation of MuRF1 expression by Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) has been postulated (Cai et al., 2004), and evidence suggestive of NF-κB activation in atrophying muscle has been described in both underweight and cachetic COPD patients (Agusti et al., 2004; Vogiatzis et al., 2010). Recently, increased atrogin-1 protein expression in muscle-atrophied COPD patients was associated with elevated expression and activity of the mitogen activated protein kinases (MAPK) p38, ERK 1/2 and JNK, which inversely correlated with mid-thigh cross-sectional area (Lemire et al., 2012). However, others found no differences in MAPK expression or activation in muscle biopsies of COPD patients with muscle wasting (Fermoselle et al., 2012; Riddoch-Contreras et al., 2012). Of importance, conclusive evidence for a direct role of MAPKs in UPS-mediated proteolysis in conditions of muscle atrophy, as well as putative regulatory mechanisms of E3 Ub-ligase expression in COPD remain to be established.

2.1.2. Muscle protein synthesis regulation in COPD

The insulin-like growth factor-1 (IGF-1)-Akt signaling cascade is an essential pathway in muscle maintenance and growth, as it suppresses muscle proteolysis and stimulates muscle anabolism and hypertrophy (Glass, 2005). Circulating IGF-1 levels were not altered in between mild, moderate and severe COPD patients when compared to controls (Pielh-Aulin et al., 2009), or in cachetic vs non-cachetic patients (Debigare et al., 2003). However, serum IGF-1 levels were decreased during an acute exacerbation (Cruil et al., 2007; Kythreotis et al., 2009), an episode during which skeletal muscle wasting may be accelerated in COPD patients (Remels et al., 2012). Control of muscle IGF-1/Akt signaling and muscle plasticity responses have been attributed to locally produced IGF-1 (Shavlakadze et al., 2005). In line with this notion, decreased IGF-1 expression levels corresponded with decreased muscle mass in cachetic compared to non-cachetic COPD patients (Vogiatzis et al., 2010). Decreased IGF-1 expression was also reported in muscle biopsies obtained from patients hospitalized for an acute exacerbation (Cruil et al., 2007). Nevertheless, in atrophied muscle of COPD patients with preserved fat mass increased rather than decreased muscle IGF-1 mRNA levels were observed. (Lewis et al., 2011). Interestingly, despite increased IGF-1 mRNA expression, Akt phosphorylation levels were not altered, suggesting impairments in the IGF-1/Akt signaling axis. Moreover, a counterintuitive raise in Akt activity levels reported in peripheral muscle of cachetic patients was accompanied by elevated rather than decreased atrogin-1 and MuRF1 expression levels (Doucet et al., 2007; Vogiatzis et al., 2010), which contrasts the postulated suppressive effects of Akt signaling on the expression of these E3 Ub-ligases (Glass, 2005). Intriguingly, increased phosphorylation of downstream mediators of mRNA translation, 4E-BP1 and P70S6K reflected increased Akt activity in atrophied skeletal muscle. These adaptations were interpreted as a futile cellular attempt to restore muscle mass in cachetic COPD muscle (Doucet et al., 2007). Of importance, some of the discrepant findings may relate to the heterogeneity of the studied populations with respect to body composition, COPD phenotype, severity and phase of the disease, e.g. during or following a disease exacerbation vs stable disease. In addition, incorporating assessment of muscle protein synthesis and degradation rates in combination with analyses of the regulatory pathways of protein turnover will allow to determine whether, and at which level of regulation, anabolic and anti-catabolic therapeutic strategies should be directed.

2.2. Myonuclear turnover in COPD

The concept of a ‘myonuclear domain’ (a given nucleus only controls a certain volume of cytoplasm) implies that a myofiber, upon loss or gain of volume, will have to adapt its nuclear content (Allen et al., 1999). Consequently, loss of muscle mass may not only rely on changes in protein metabolism, but may also involve changes in loss and accretion of myonuclei in muscle fibers. Although the exact mechanisms remain to be identified, loss of myonuclei is postulated to result from apoptotic events. Accretion of myonuclei on the other hand is the result of fusion of mononuclear myoblasts with adjacent myofibers. These cells arise from locally residing ‘satellite cells’, proliferate and subsequently differentiate under the influence of myogenic differentiation factors.

2.2.1. Muscle cell apoptosis in COPD

Literature regarding peripheral muscle cell apoptosis in COPD is limited and available studies report discrepant findings. Increased DNA fragmentation in myonuclei and PARP cleavage in homogenates of muscle biopsies of underweight COPD patients compared to normal-weight patients or healthy controls were suggestive of increased apoptosis (Agusti et al., 2002; Barreiro et al., 2011). Of three apoptotic markers, only myonuclear DNA fragmentation was consistently increased in muscle of patients with severe COPD but normal weight and body composition (Agusti et al., 2002; Barreiro et al., 2011). In contrast, in muscle-atrophied patients myonuclear DNA fragmentation and active caspase-3 levels as additional marker of apoptosis were not different compared to controls (Gosker et al., 2003). However, in this study, myofiber atrophy was accompanied by mild fibrosis and replacement of myofibers by adipocytes. Fibroblast and adipocyte replacement are myopathological features observed in muscular dystrophies, and considered a consequence of satellite cell depletion following continuous rounds of muscle regeneration.

2.2.2. Myonuclear accretion and muscle regeneration in COPD

Although satellite cell numbers are not decreased in normal weight COPD patients with (Eliaison et al., 2009) or without (Menon et al., 2012) type II myofiber atrophy, satellite cell senescence has been reported in muscle biopsies of patients with severe COPD (Theriault et al., 2012). This is consistent with the notion of a decreased myogenic potential of skeletal muscle of COPD patients. However, satellite cell proliferation in response to an acute bout of resistance exercise was not different in patients with maintained muscle mass compared to healthy subjects (Menon et al., 2012).

Impaired muscle regeneration may contribute to muscle atrophy in COPD, as it inhibits myonuclear accretion of myofibers, limiting their capacity for (re)growth. In addition to satellite cell
activation and proliferation, subsequent myogenic differentiation and myoblast fusion is essential for muscle regeneration. mRNA levels of myogenic differentiation factors Myf5, MyoD and myogenin were unaltered in peripheral muscle of muscle-atrophied COPD patients compared to controls (Plant et al., 2010). However, muscle myogenin expression was lower in cachectic patients compared to controls and MyoD protein levels were significantly decreased in cachectic versus non-cachectic COPD patients (Fermonselle et al., 2012; Vogiatzis et al., 2010). In addition, patients experiencing an acute exacerbation displayed reduced muscular levels of MyoD mRNA and protein compared to healthy controls (Cruel et al., 2007). Myostatin is expressed and secreted by skeletal muscle (Hittel et al., 2009) and is a member of the Transforming Growth Factor (TGF)-beta superfamily, which suppresses muscle growth by acting at multiple levels, including inhibition of satellite proliferation and myogenic differentiation (Kollias and McDermott, 2008). Circulatory myostatin levels were elevated in COPD patients compared to controls and correlated inversely with muscle mass (Ju and Chen, 2012). Myostatin mRNA expression in peripheral muscle was increased in muscle-atrophied COPD patients compared to controls (Plant et al., 2010) and inversely correlated with quadriceps strength in COPD patients (Man et al., 2010). Protein levels of myostatin however, were unchanged in muscle of cachectic versus non-cachectic patients (Vogiatzis et al., 2010). As no healthy controls were included in that study, it remains to be determined whether alterations in myostatin expression precede muscle atrophy in COPD.

Muscle regenerative capacity may be reflected by training-induced myogenic responses. Normal-weight COPD patients and controls displayed similar training-induced increases in peak work rate and muscle expression of MyoD mRNA, MyoD protein and myogenin mRNA (Lewis et al., 2007; Vogiatzis et al., 2007). Moreover, a reduction in myostatin mRNA levels upon pulmonary rehabilitation in combination with testosterone supplementation was observed in normal-weight COPD patients (Lewis et al., 2007), indicating that muscle of COPD patients can mount a myogenic response upon training. Interestingly, rehabilitation-induced increases in MyoD mRNA occurred both in cachectic and non-cachectic patients, while MyoD protein only increased in non-cachectic patients (Vogiatzis et al., 2010). On a similar note, quadriceps myostatin mRNA and protein expression were reduced in non-cachectic and normal-weight patients, but not in cachectic COPD patients, upon resistance training or pulmonary rehabilitation respectively (Troosters et al., 2010; Vogiatzis et al., 2010). This was accompanied by a significant attenuation in myofiber size growth in the latter group, suggesting an impaired capacity for muscle regeneration and peripheral muscle mass recovery in response to exercise training in cachectic patients.

Although it remains to be addressed whether and to what extent alterations in myonuclear turnover determine changes in muscle mass, overall the studies discussed here suggest it may be impaired in atrophying muscle in COPD. Restoring myogenic responses may further improve effects of pulmonary rehabilitation on recovery of muscle mass in cachectic COPD patients.

3. Zeroing in on the putative triggers of muscle wasting in COPD

The apparent discrepancies between studies and heterogeneity in the underlying processes of muscle wasting in COPD may be attributable to the multitude of factors capable of inducing muscle atrophy. These factors may occur in isolation or in concert during different phases of the disease. Putative triggers of muscle wasting in COPD include diabetes, hypoxemia, malnutrition, inflammation and endogenous as well as synthetic glucocorticoids. These may be a direct consequence of the decreased function and pathological remodeling of the diseased lung, e.g. hypoxemia and pulmonary inflammation, or may concern physiological and behavioral mal-adaptations, e.g. disuse and malnutrition. During disease exacerbations these factors converge and, together with synthetic glucocorticoids as a common medical intervention, may synergize to accelerate muscle wasting. Fig. 1 provides an overview of the pathways and processes affected by these triggers and how they may contribute to muscle wasting in COPD.

3.1. Disuse

A sedentary lifestyle is a common characteristic of COPD (Vorrink et al., 2011) and has profound effects on peripheral skeletal muscle mass and function. Already in mild COPD, physical inactivity was independently associated with quadriceps wasting (Shrikrishna et al., 2012). Moreover, disease exacerbations are accompanied by reduced levels of physical activity (Pitta et al., 2006). Inactivity was not only attributable to bed rest during hospitalization as a sustained reduction in physical activity level was still observed more than a month following discharge (Donaldson et al., 2005).

Inactivity, muscle disuse and unloading are well-documented triggers of muscle atrophy. These have been modeled in humans by limb immobilization or suspension, or by enforcing sustained bed rest, which is followed by significant muscle atrophy and reduced muscular strength (Murton and Greenhaff, 2010). Both decreased protein synthesis and increased proteolysis have been reported in skeletal muscle during disuse atrophy. However, in contrast to protein synthesis, the changes in proteolysis in disuse atrophy may be transient in nature. Increased ubiquitin conjugates and MuRF1 and atrogin-1 mRNA transcript levels were observed 48 h following initiation of limb immobilization in both young and aged healthy volunteers (Abadi et al., 2009; Glover et al., 2010; Suetta et al., 2012). In conjunction, elevated intramuscular interstitial levels of 3-methylhistidine were detected 72 h after initiation of a similar protocol (Tesch et al., 2008). In contrast, there is less evidence to support a sustained increase in proteolysis rates during sustained inactivity. Although the expression of some transcripts encoding UPS components, including atrogin-1 but not MuRF1, was increased 14 days following initiation of limb immobilization (Jones et al., 2004), these changes were not observed in similar studies. Moreover, MuRF1 and atrogin-1 levels were even decreased in healthy aged subjects compared to baseline (Abadi et al., 2009; Suetta et al., 2012). Similarly, atrogin-1 and MuRF1 expression levels were not increased following 24 days of bed rest (Brocca et al., 2012). This clearly differs from the reports describing increased expression levels of these E3 Ub-ligases in muscle wasting in stable COPD, indicating that these alterations are unlikely to result from sustained disuse. Conversely, increased expression of Nedd4 in atrophied COPD muscle (Plant et al., 2010) may be the consequence of muscle disuse, as this E3 Ub-ligase was reported to be selectively elevated in experimental models of inactivity or unloading-induced muscle atrophy (Koncarevic et al., 2007). However, the contribution of Nedd4 to muscle wasting is currently unclear, as opposing results were reported regarding its requirement in disuse atrophy in experimental models (Koncarevic et al., 2007; Nagpal et al., 2012).

Atrogin-1 and MuRF1 are essential for inactivity- and unloading-induced muscle atrophy (Bodine et al., 2001), and their rapid induction following disuse has been attributed to transcriptional regulation by NF-κB and FOXO (Cai et al., 2004; Senf et al., 2010; Wu et al., 2011). The underlying mechanism of NF-κB activation in disuse atrophy has not been clarified, but altered mechanical tension and subsequent oxidative stress have been implicated as potential triggers (Dodd et al., 2010; Powers et al., 2012). Oxidative stress (Fermonselle et al., 2012) and evidence of NF-κB
activation have been demonstrated in muscle wasting in COPD, but it remains to be established whether they co-occur and are related to disuse. Although NF-κB signaling is required for inactivity- and unloading atrophy (Cai et al., 2004; Van Gammeren et al., 2009), p50 and Bcl-3 have been identified as the constituents of the NF-κB complex responsible for transcriptional regulation of muscle atrophy in response to disuse (Wu et al., 2011). This may differ from immune response-associated canonical NF-κB signaling, which relies on the RelA-p50 hetero dimer. Activation of FOXO in response to disuse has been attributed to oxidative stress (Dodd et al., 2010). In addition, decreased IGF-1/Akt signaling also results in transcriptional activation of FOXO (Sandri et al., 2004). In atrophied muscle of COPD patients increased nuclear presence of FOXO has been described (Doucet et al., 2007), although this was accompanied by increased rather than decreased Akt phosphorylation, suggesting FOXO activation through non-canonical signaling routes. In addition, reduced IGF-1/Akt signaling will result in decreased mTOR/4E-BP1/p70S6K1 activity (Rommel et al., 2001) and subsequent inhibition of mRNA translation initiation, which lies at the basis of attenuated protein synthesis rates in disuse atrophy. However, whether this is applicable to COPD-associated muscle wasting remains to be determined, as indirect indices of protein synthesis signaling including Akt, 4E-BP1 and p70S6K1 phosphorylation were either unaltered (Plant et al., 2010) or even increased (Doucet et al., 2007), which is difficult to reconcile with decreased protein synthesis as observed in disuse atrophy.

Pulmonary rehabilitation is an intervention based on individually tailored exercise training and aims at improving exercise capacity and health status in COPD patients. In addition to improving endurance and fatigability, exercise training increases muscle strength, muscle mass, and muscle fiber size (Man et al., 2009). Although these effects of exercise training suggest a causal involvement of physical inactivity and disuse in muscle wasting, exercise training does not fully reverse all of the abnormalities observed in the peripheral muscle in COPD (Man et al., 2009). In cachectic COPD patients, exercise training-induced increases in myofiber size and muscle IGF-1 expression were significantly attenuated compared to non-cachectic COPD patients, which was accompanied by respectively down-regulation of myostatin and an induction of MyoD expression, only in non-cachectic patients (Vogiatzis...
et al., 2010). Moreover, up to one-third of the patients do not respond to pulmonary rehabilitation in terms of improved exercise capacity and muscle strength (Decramer, 2008). This suggests the presence of disease-related factors interfering with the effect of exercise training, or alternatively, the existence of triggers other than inactivity responsible for muscle wasting in this population of non–responding COPD patients. In addition, whereas inactivity correlated with muscle wasting in mild disease, these were not independently associated in more advanced COPD (Shrikirksna et al., 2012). Moreover, the specific type IIX fiber atrophy in COPD excludes a predominant involvement of physical inactivity, as disease-induced reductions in muscle mass are characterized by type I muscle fiber atrophy (Hather et al., 1992). Altogether, this suggests that, although disuse may contribute to muscle atrophy associated with the milder stages of the disease and during hospitalization for acute disease exacerbations, additional factors besides inactivity drive muscle wasting in COPD.

3.2. Hypoxemia

Hypoxemia, i.e. reduced arterial oxygen tension, is an obvious consequence of respiratory failure, but surprisingly its potential impact on muscle maintenance in patients with COPD is rather unexplored. The prevalence of hypoxemia in COPD remains uncertain: although severe hypoxemia is estimated at 2% of the patient population (Tashkin et al., 2008), little data exist on the prevalence of intermittent, e.g. nocturnal and exertional hypoxemia. In addition, acute exacerbations are often accompanied by deterioration of pulmonary gas exchange, resulting in severe transient hypoxemia (Curtis and Hudson, 1994). Long-term oxygen treatment is accompanied by improvements in muscle function of hypoxemic COPD patients (Davidson et al., 1988), although reports assessing effects on muscle mass are lacking. Moreover, hypoxemia occurs more frequently in patients with emphysema compared to chronic bronchitis, with muscle wasting being more prevalent in the emphysematous subtype (Engelen et al., 1994).

Currently most of the evidence implying hypoxemia and subsequent tissue hypoxia as triggers of muscle wasting is derived from studies in healthy subjects and experimental models. Observations in mountaineering expeditions in which subjects were exposed to high altitude hypoxia reported decreased muscle mass (Hoppeler et al., 1990) and reduced muscle fiber size, regardless of physical activity levels (Mizuno et al., 2008). Similarly, simulated hypobaric hypoxia resulted in reductions in muscle mass and fiber cross-sectional area (MacDougall et al., 1991). In humans as well as in animals exposed to hypoxia, reduced appetite and decreased food intake (hypophagia) have been described (Chaudhary et al., 2012; Favier et al., 2010; Westerterp-Plantenga et al., 1999). The expression of the satiety hormone leptin is controlled, in part, by the transcriptional regulator hypoxia inducible factor 1α (HIF1α), and alterations in circulating leptin levels have been reported for cachectic COPD patients with more severe hypoxemia (Takahatake et al., 2001). Although these anorexic effects of hypoxia may contribute to muscle wasting as well, reductions in muscle mass independent of hypophagia have also been reported.

At the cellular level, adaptive responses to severe hypoxia include down-regulation of energy-consuming processes such as protein synthesis. Hypoxia suppresses protein synthesis at multiple levels, including inhibition of Mammalian target of rapamycin (mTOR) activity. This involves Regulated in development and DNA damage responses-1 (REDD1), as well as the sensor of cellular energy balance 5′-adenosine monophosphate-activated protein kinase (AMPK) (Li et al., 2006; McGee and Hargreaves, 2010). Both REDD1 and AMPK inhibit mTORC1 through phosphorylation of the tuberous suppressor complex 2 (TSC2), which reinforces inhibition of mTORC1. Subsequent decreases in phosphorylation levels of p70S6K1 and 4E-BP1 result in reduced mRNA translation initiation and suppression of protein synthesis (Laplante and Sabatini, 2012). Most of these insights in the molecular control of protein synthesis by hypoxia stem from work related to tumor cell biology (Wouters and Korsitzyns, 2008). In those studies, predominantly severe hypoxic (<1.5% O2) or even anoxic (<0.02% O2) conditions were investigated, which may contribute to some discrepant findings of hypoxia in skeletal muscle described below. Muscle atrophy in rats subjected to hypoxia was accompanied by reduced mTOR, S6 but not 4E-BP1 phosphorylation, and this coincided with increased REDD1 expression (Favier et al., 2010). Interestingly, AMPK phosphorylation was reduced, illustrating decreased rather than elevated activity of this enzyme in response to chronic hypoxia in skeletal muscle. In this same study, the authors correlated decreased S6 phosphorylation in skeletal muscle of hypoxemic COPD patients with an increase (although non-significant) in a surrogate marker of REDD1 activity. Similarly, muscle REDD1 mRNA transcripts were increased in healthy subjects in response to 4h of hypoxia, although this was accompanied by contradicting elevations in Akt and p70S6K1 phosphorylation levels (D’hulst et al., 2013). In line with this, increased muscle protein synthetic rates were detected in rats exposed to hypoxia. However, muscle mass still decreased regardless of increased protein synthesis, which was attributed to even greater elevations of muscle proteolysis (Chaudhary et al., 2012). Muscle atrophy in this study was accompanied by an elevation in Ub conjugates and UPS-associated proteolytic activity. Nevertheless, increased MuRF1 and atrogin-1 mRNA transcript levels have thus far only been reported in cardiac muscle in response to hypoxia (Razeghi et al., 2006). In addition, small increases in calpain– and lysosomal–associated proteolysis were detected following hypoxia in skeletal muscle. The latter may indicate the potential involvement of the autophagy–lysosomal system (ALS) in muscle proteolysis. This is of particular interest, as an increased autophagic flux is a well-characterized response of multiple cell types to hypoxia and essential for survival (Rouschop and Wouters, 2009). As studies addressing a contribution of autophagy to muscle atrophy associated with a variety of conditions are only recently emerging, its potential role in muscle alterations and wasting in COPD (Hussain and Sandri, 2012) will undoubtedly be scrutinized in due time.

Little information is available regarding the effects of hypoxia on myonuclear turnover. No evidence for in vivo myofiber apoptosis was observed following hypoxia (Riva et al., 2001). In addition, proliferative and myogenic potential of ex vivo cultured satellite cells was even improved under hypoxic conditions compared to culture in ambient oxygen levels, although hypoxia as applied here may rather reflect the physiological oxygen tension encountered by satellite cells in vivo (Urbani et al., 2012). Preferential stimulation of myoblast proliferation at the expense of myogenic differentiation in response to hypoxia has been reported, and was attributed to hypoxia-induced redirection of IGF-1/Akt to IGF-1/ERK signaling, in which Akt is controlled by oxygen levels independent of HIF1α (Majmundar et al., 2012; Ren et al., 2010). Hypoxia may directly impair myogenesis by reducing MyoD protein stability, or indirectly by inducing myostatin expression as documented in skeletal muscles of hypoxic COPD patients or rats exposed to chronic hypoxia (Di Carlo et al., 2004; Hayot et al., 2011). In addition, decreased regenerative potential of satellite cells obtained from skeletal muscle of hypobaric hypoxia exposed healthy subjects has been reported (Mancinelli et al., 2011).

A systems biology approach revealed an impaired muscle tissue remodeling response in COPD following an eight week training protocol (Turan et al., 2011). Although these COPD patients were not hypoxic, network analyses revealed a set of aberrantly expressed oxygen-dependent histone modifiers, which have been implicated in tissue remodeling, including myogenesis. Reduced
myogenic potential has also been suggested by decreased myogenin and MyoD expression in atrophied skeletal muscle of COPD patients, but clearly the causal involvement of hypoxia remains to be addressed (Ferroselle et al., 2012; Vogiatzis et al., 2010). Collectively, these studies indicate that tissue hypoxia undoubtedly affects muscle protein and myonuclear turnover. However, identification of the essential effectors and regulators of hypoxic responses involved in skeletal muscle plasticity and their molecular signatures will be required in order to elucidate the potential contribution of tissue hypoxia to muscle wasting in COPD.

3.3. Malnutrition

Malnutrition is reported in one-third of the COPD population, which may be severe with advanced disease (Ferreira et al., 2012). Malnutrition is the result of an imbalance between dietary energy intake and expenditure, and increased total energy expenditure has been reported in clinically stable COPD (Baarends et al., 1997b). In addition, reduced caloric intake is pronounced during COPD exacerbations, while accompanied by an increase in resting energy expenditure (REE) (Vermeeren et al., 1997). The energy imbalance and subsequent catabolic state as a consequence of anorexia and increased REE may result from increased circulating leptin levels, which have been reported in cachetic COPD patients and during acute exacerbations of the disease and appear to be related to hypoxemia and systemic inflammation (Creutzberg et al., 2000b; Schols et al., 1999; Takabatake et al., 2001).

Positive effects of nutritional supplementation suggest that loss of FFM in COPD may, to some extent, be attributable to malnutrition although for most subjects increasing energy intake alone did not improve skeletal muscle mass (Ferreira et al., 2012; Schols et al., 1995). A sub-population of COPD patients is characterized by preferential loss of skeletal muscle mass with relative preservation of fat mass (Schols et al., 2005). This contrasts physiological adaptations in response to fasting and starvation, which involve successive post-absorptive utilization of glycogen reserves and oxidation of fat, with relative sparing of muscle protein until the final stages of starvation. Of note, fasting is initially accompanied by a transient increase in muscle proteolysis (Goodman et al., 1984). The release of AA by skeletal muscle supports gluconeogenesis and serves as an energy source for other tissues and organs, and in response to fasting increased muscle proteolysis appears mainly the consequence of increased cortisol paralleled by decreased insulin levels (Wing and Goldberg, 1993). Subsequent reductions in muscle insulin/IGF-1 receptor activation and signaling culminate in decreased Akt enzymatic activity, which affects cytosolic retention of FOXO (Stitt et al., 2004). The resulting nuclear translocation of FOXO drives the expression of key regulators of both UPS and ALS-mediated proteolysis. Although increases in nuclear FOXO abundance have been reported in skeletal muscles of COPD patients, this was in presence of unaltered or even increased rather than decreased Akt phosphorylation, suggesting that FOXO activation was unlikely to reflect starvation-induced muscle proteolysis regulatory cues (Doucet et al., 2007; Plant et al., 2010). Muscle protein synthesis decreases in response to starvation, and although one study reported a reduction of whole-body protein synthesis in underweight COPD patients (Morrison et al., 1988), later studies analyzing the regulatory pathways of protein synthesis in muscle tissue are not in support of reduced muscle protein synthetic rates: 4E-BP1 phosphorylation, a rate limiting step in mRNA translation, which decreases in response to starvation (Shah et al., 2000), was not affected or even increased in atrophied skeletal muscle of COPD patients (Doucet et al., 2007; Plant et al., 2010).

There is only limited data on effects of malnutrition on myonuclear turnover. Limited AA concentrations, and in particular inadequate branched chain AA availability inhibits myogenic differentiation (Averous et al., 2012; Haegens et al., 2012), and some evidence of suppressed myogenic activity has been reported in response to prolonged fasting (Jeanplong et al., 2003). Impaired myogenesis following AA deprivation may involve decreased MyoD expression, but also attenuated protein synthesis signaling. Interestingly, myostatin signaling conveys similar effects (McFarlane et al., 2011; Fransenbourg et al., 2009), but solid evidence implicating myostatin as a mediator of fasting-induced muscle atrophy is currently lacking.

Therefore, to clarify a potential contribution of malnutrition to muscle wasting in COPD, muscle protein turnover measurements with combined analyses of the signaling pathways that govern muscle protein metabolism and myogenesis should be incorporated in nutritional intervention studies conducted in malnourished COPD patients. In addition, it remains to be investigated whether the physiological adaptive responses to reduced caloric intake are intact in COPD, or whether these are aggravated by the interaction with other disease-related triggers of muscle wasting.

3.4. Inflammation

COPD is often associated with a chronic low-grade inflammatory state with increased circulating levels of tumor necrosis factor-alpha (TNF-α), soluble TNF-α receptors (sTNF-R), C-reactive protein (CRP) and interleukin (IL) 1β and IL-6 being reported (Nussbaumer-Ochsner and Rabe, 2011). Elevated circulating levels of TNF-α and its soluble receptors have been associated with acute weight loss and reduced lean mass (Di Francia et al., 1994; Eid et al., 2001). Also, a more pronounced systemic inflammatory response to exercise was observed in cachetic patients compared to non-cachetic patients (van Helvoort et al., 2006). Whether systemic inflammation is the result of spill-over from inflammatory processes in the diseased lung remains to be resolved, as pulmonary and circulating levels of inflammatory mediators did not correlate (Vernooy et al., 2002), suggesting a potential contribution of other sources including circulating leukocytes or adipose tissue (Oudijk et al., 2005; van den Borst et al., 2012). Interestingly, increased serum levels of TNF-α and its soluble receptors were associated with hypoxemia in underweight COPD patients (Takabatake et al., 2000). In experimental models of chronic smoke exposure- or pulmonary inflammation-induced emphysema, moderate to severe muscle wasting was associated with systemic inflammation, including raised serum levels of TNF-α and its receptors (De Paepe et al., 2008; Gosker et al., 2009; Langen et al., 2006; Tang et al., 2010b).

Systemic inflammation, and in particular increased circulating TNF-α levels, has been implicated in various conditions accompanied by muscle atrophy (Moldawer et al., 1983; Tracey et al., 1988). Pro-inflammatory cytokines may induce muscle catabolism via a relay based on hypothalamic-pituitary-adrenal (HPA) axis activation, and subsequent glucocorticoid release (as will be discussed below) and proteolysis signaling in skeletal muscle (Braun et al., 2011). Nevertheless, exposure of cultured myotubes to TNF-α alone or a cocktail of pro-inflammatory cytokines implicated a cell autonomous response in inflammation-induced muscle atrophy, mediated by NF-κB activation (Guttridge et al., 2000; Li and Reid, 2000). Constitutive activation of canonical NF-κB signaling in skeletal muscle caused muscle atrophy in mice, providing further support of an important role of NF-κB in muscle mass regulation (Cai et al., 2004). Contradicting findings on NF-κB activity status in muscle biopsies of COPD patients have been reported (Agusti et al., 2004; Merckx et al., 2011; Plant et al., 2010). These inconsistent alterations in muscle NF-κB activity levels in COPD patients compared to controls may reflect differences in phases of the disease accompanied by decreased but stable muscle mass vs acute muscle loss. The latter likely occurs during COPD exacerbations,
considering the activation of the UPS reported in these episodes of the disease (Crlu et al., 2010).

Indeed, pulmonary and systemic inflammation was more pronounced during acute exacerbations (Oudijk et al., 2006; Wouters et al., 2007). In addition, induction of acute pulmonary inflammation in animal studies is sufficient to trigger muscle atrophy, which was accompanied by systemic inflammation and muscle NF-κB activation (Files et al., 2012; Langen et al., 2012). Genetic inhibition of muscle NF-κB activity markedly blunted the induction of MuRF1 expression, and genetic suppression of MuRF1 expression ameliorated muscle atrophy. This suggests that increased UPS-mediated proteolysis is responsible for NF-κB-dependent muscle atrophy following acute pulmonary inflammation. In line with that notion, elevated NF-κB activation correlated with total muscle protein ubiquitination in quadriceps muscle of cachectic COPD patients (Fermsolle et al., 2012). Additional inflammatory mediators and signaling pathways, including TWEAK (Dogra et al., 2007), IL-17 and TLR-4 (Doyle et al., 2011; Tang et al., 2010a), and IL-6/STAT3 (Bonetto et al., 2011) have been implicated in inflammation-associated muscle proteolysis, but their presence and activation remains to be addressed in COPD-associated muscle wasting. In addition to enhancing proteolysis, inflammatory mediators may contribute to muscle atrophy through inhibition of protein synthesis (Williamson et al., 2005).

An inappropriate or unresolved inflammatory response may also cause suppression of myogenesis and impaired muscle regeneration. Studies in support of this latter notion revealed inhibition of muscle differentiation and regeneration upon TNF-α administration, which involved NF-κB dependent suppression of MyoD mRNA and MyoD protein destabilization (Guttridge et al., 2000; Langen et al., 2004). Interestingly, impaired muscle mass recovery in response to training was noted in cachectic COPD patients, which was accompanied by decreased MyoD expression and evidence of elevated NF-κB activity (Vogiatzis et al., 2010). Moreover, an impaired muscle regenerative response during recovery from disuse atrophy was also observed in emphysematous mice with systemic inflammation (Langen et al., 2006). Although the causal interference of inflammation with muscle mass recovery requires further investigation, it is interesting to draw a parallel with a study in which COPD patients who failed to gain weight in response to pulmonary rehabilitation, were characterized by elevated circulating levels of inflammatory mediators (Creutzberg et al., 2000a).

3.5. Glucocorticoids

As mentioned earlier, endogenous glucocorticoids (GCs) are required for muscle proteolysis associated with starvation and may contribute to inflammation-associated muscle atrophy. Synthetic, exogenously administered corticosteroids represent an additional modus by which GCs constitute a putative trigger of muscle atrophy relevant to COPD-associated muscle wasting. GCs are frequently applied during acute exacerbations for their anti-inflammatory properties and are sometimes used as maintenance treatment during end-stage disease. The efficacy of GCs as maintenance medication is controversial (Vestbo et al., 2013), and its use is associated with a dose-dependent increase in mortality risk in severe disease (Schols et al., 2001). Moreover, the use of GCs may affect skeletal muscle force and correlates with a decline in FFM independently of disease severity (Decramer et al., 1996; Hopkinson et al., 2007).

GCs and IGF-I signaling have opposing effects on muscle mass maintenance, and the molecular basis of their antagonistic effects has been clarified to some extent. Muscle IGF-I expression is suppressed by GCs (Schakman et al., 2008), whereas over-expression of muscle IGF-I prevents GC-induced muscle atrophy (Gilson et al., 2007; Schakman et al., 2005). Reduced IGF-I expression levels have been reported in muscle of patients during an exacerbation who were receiving oral corticosteroids (Crlu et al., 2007).

GC signaling directly affects muscle protein turnover, which involves ‘genomic and non-genomic’ actions of activated GC receptor (GR). In this context, the best described non-genomic effects of GR activation rely on impairment of IGF/ Akt signaling by interference of IRS-1–PI-3K association by GR (Hu et al., 2009). This was postulated to result in subsequent derepression of FOXD and suppression of mTOR activity consequent to decreased Akt signaling, which coordinately increases proteolysis and decreases protein synthesis. Conversely, genomic effects of GR activation related to protein turn over include impairments of IGF-I signaling up- and downstream of Akt. GCs increase expression of the inhibitory P85α subunit of the PI-3K complex, which requires GR-dependent transcriptional activation of P85α and result in suppression of Akt activity (Kuo et al., 2012). GR-dependent transcription of REDD1 impinges mTOR activity, further reinforcing GC-mediated inhibition of IGF-1 expression and signaling downstream of Akt, and a subsequent reduction of protein synthesis (Kumari et al., 2011). In addition, FOXD transcription is increased by GR activation and this de novo expressed FOXO may override Akt-mediated nuclear exclusion resulting in increased FOXO-mediated atrogen-1 and MuRF1 expression (Shimizu et al., 2011). Moreover, increased expression of these atrogenes in response to GCs is dependent on GSK3β, providing another level of IGF-1–GC cross-talk downstream of Akt (Schakman et al., 2008; Verhees et al., 2011). Myostatin expression is induced by GC signaling in skeletal muscle, and GC-induced muscle atrophy and proteolytic signaling is prevented in absence of myostatin (Gilson et al., 2007). As glucocorticoids are often administered during an acute exacerbation, increased myostatin expression could be anticipated in skeletal muscle of patients during COPD exacerbations, but currently no reports have assessed this. Increased myostatin expression has been reported in muscle of cachectic COPD patients with stable disease (Fermsolle et al., 2012).

GR DNA binding elements (GREs) have been identified in the promoter regions of the MuRF1 and myostatin genes, which in case of MuRF1 are required for full transactivation by GCs (Du et al., 2005; Waddell et al., 2008). Although MuRF1 and myostatin mRNA levels are elevated in atrophying COPD muscle, the contribution of relevant triggers other than GCs can not be ruled out as transcriptional regulatory elements in addition to GREs have been described in enhancer regions of these genes. In contrast, REDD1 expression has been postulated as a surrogate marker for muscle GR signaling (Kumari et al., 2011). Consequently, increased REDD1 expression observed in muscle of acutely hypoxemia COPD patients and hypoxia-exposed animals (Favier et al., 2010) may reflect increased cortisol or corticosterone levels that accompany hypoxemia (Chen et al., 2007; Raff and Levy, 1986).

GC signaling may also exert regulatory cues on muscle mass by affecting myonuclear turnover. Some evidence of myofiber apoptosis has been described in GC-induced myopathy (reviewed in Dirks-Naylor and Griffiths, 2009). Conversely, GC-mediated inhibition of myogenesis may impair myonuclear accretion, which not only interferes with muscle maintenance but also recovery of muscle mass (Pansters et al., 2012; Qin et al., 2010). Indeed, a gain in lean mass typically observed in response to pulmonary rehabilitation was absent in COPD patients using GCs (Creutzberg et al., 2003; Pansters et al., 2012).

A more comprehensive analysis of GR-dependent gene expression and non-genomic GR actions in skeletal muscle of COPD patients during stable disease and acute exacerbations will contribute to elucidating the potential contribution of GCs and increased GC signaling to muscle wasting in COPD.
4. Conclusion and future directions

Although our insights in the pathobiology of muscle wasting in COPD has significantly improved the last two decades, contradicting findings in alterations of the processes that govern muscle mass complicate the formulation of targeted intervention strategies. Some of the discrepancies may result from confounding effects of co-morbidities or the uncontrolled use of drugs that possibly affect muscle anabolism, like long-acting beta-2 agonists (MacLennan and Edwards, 1989). It is, however, essential to realize that apparent inconsistencies may be attributable to an intrinsic heterogeneity between COPD patients. These may in particular concern differences in (vulnerable) COPD sub-populations, e.g. cachectic emphysematous patients and relative obese patients with muscle atrophy (sarcopenic obesity), with specific characteristics that may impair muscle mass maintenance, such as hypoxemia or an altered adipose secretome. Systems biology and signaling pathway analyses approaches based on transcriptomic, proteomic and metabolomic assessments of muscle biopsies are a promising venue to identify divergent processes of muscle mass regulation in atrophying muscle in COPD based on coherent molecular signatures rather than single markers. In addition, pathway analyses approaches applied to muscle biopsy material may also prove extremely useful in identifying the disease-related triggers of muscle wasting.

COPD muscle wasting may involve a non-continuous reduction rather than a gradual decrease of muscle mass. Therefore the time-course of muscle wasting requires to be defined at higher resolution, as muscle atrophy may accelerate during exacerbations, while subsequent periods of clinically stable disease are characterized by impaired recovery of muscle mass. Such a biphasic course of muscle wasting is likely governed by separate processes, as acute exacerbations may involve muscle mass loss resulting from increased proteolysis, whereas sustained muscle atrophy may not recover during stable disease as a consequence of impaired responsiveness to signaling cues of muscle regeneration and protein synthesis. To address this potential differential involvement of processes that govern muscle mass in the distinct phases of muscle wasting in COPD, longitudinal studies to assess the course of muscle wasting in COPD should be combined with measurements of muscle protein turnover and supplemented with measures of satellite cell activity and myonuclear accretion. Of note, collecting biopsies of patients solely in static, resting conditions may not suffice: the concept that impaired responsiveness to anabolic stimuli compromises muscle mass recovery in COPD patients with stable disease and muscle atrophy could for instance be addressed by evaluating the ability of skeletal muscle to mount an appropriate protein synthetic response or satellite cell activation following an acute bout of exercise (Menon et al, 2012; Snijders et al., 2012; Wirat et al., 2009).

A non-gradual course of muscle atrophy also has ramifications for the selection of experimental models appropriately reflecting the pathobiology of COPD-associated muscle wasting. Traditionally, chronic smoke exposure- or elastase instillation-induced emphysema in rodent models has been adopted to study cellular and molecular changes in skeletal muscle (Gosker et al., 2009; Mattson et al., 2004). However, the experimental models may require further refinement in order to more truthfully recapitulate the processes underlying COPD (Stevenson and Birrell, 2011) and in particular COPD-associated muscle wasting. For instance, in order to model exacerbation-associated alterations in skeletal muscle mass, a chronic smoke exposure model is not appropriate, but may require the addition of an infectious component or hypoxicemic conditions, to more closely mimic the pulmonary changes associated with COPD exacerbation. Such an effort, deployed in combination with genetically modified mice, is essential in order to address the causal involvement of signaling molecules including NF-κB, FOXO, HIF1 and GR, that may relay muscle atrophy cues initiated by the suspected triggers of COPD muscle wasting, e.g. disuse, malnutrition, hypoxia, inflammation and glucocorticoids. Although it may prove a challenge, experimental modeling of COPD exacerbation-associated loss of muscle mass will be of particular interest, as multiple triggers of muscle atrophy do converge, which may activate synergistic and parallel signaling routes that determine muscle wasting.

Whereas these approaches are designed to identify specific triggers and their subsequent signaling routes to specifically target COPD-associated muscle wasting, the efficacy of therapeutic strategies deploying anabolic pharmacological agents aimed at restoring the (sub)cellular balance in protein and myonuclear turnover is relatively underexplored in COPD. Transient recovery of muscle mass by anabolic steroids has been reported (Casaburi et al., 2004), which, surprisingly, may synergistically interact with GCs to more potently stimulate myogenesis and muscle growth in COPD (Pansters et al., 2012). This further illustrates the necessity for experimental models with improved relevance for COPD-associated muscle wasting, as it will allow more robust pre-clinical evaluation of newly developed anabolic agents, including selective androgen receptor modulators and myostatin inhibitors, while screening for unanticipated effects resulting from the unique paillet of atrophy-inducing triggers in COPD muscle wasting.

In conclusion, significant progress has been made in understanding muscle wasting in COPD. Further examination of the time-course of muscle wasting and potential differences in patient sub-populations, as well as the application of systems biology and omics approaches in future studies is required for the development of more tailored single or multimodal strategies to prevent or reverse muscle wasting in COPD.

References


SenfSM, Dodd SL, Judge AR, FOXO signaling is required for discrete muscle atrophy and is directly regulated by Hsp70. American Journal of Physiology Cell Physiology 2006;291:C512–45.


Theriault ME, Fare ME, Maltais F, Debigrace R. Satellite cells senescence in limb muscle of severe patients with COPD. PLOS ONE 2012;7:e39124.